middle.news
Neuren gains FDA orphan status for NNZ-2591 in neonatal brain injury
10:37am on Monday 2nd of November, 2026 AEDT
•
Biotechnology and Pharmaceuticals
Read Story
Neuren gains FDA orphan status for NNZ-2591 in neonatal brain injury
10:37am on Monday 2nd of November, 2026 AEDT
Key Points
FDA orphan designation for NNZ-2591 in neonatal HIE
Potential seven-year US marketing exclusivity
Juvenile animal safety study underway
IND application planned for H1 2027
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neuren Pharmaceuticals (ASX:NEU)
OPEN ARTICLE